Novel GluN2B-NMDAR antagonist demonstrates excellent safety and efficacy in MCAO rat model
April 15, 2024
Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. published data detailing the design and biological evaluation of novel NMDAR-GluN2B antagonists as potential candidates for the treatment of ischemic stroke.